R01DA057608

Treating Polysubstance Use in Methadone Maintenance: Application of Novel Digital Technology - Abstract

Methadone is a highly effective treatment for opioid use disorder (OUD), but many patients leave treatment prematurely, placing them at high risk of relapse and overdose. Extensive research shows that comorbid cocaine use is associated with poor retention in methadone treatment.

The proposed study will examine a novel intervention designed to improve methadone treatment retention and other outcomes among people with opioid and cocaine polysubstance use. The design is a 2-arm randomized controlled trial conducted over a one-year period following methadone treatment entry.

Retention (primary) and drug use (secondary) outcomes for methadone treatment as usual (TAU, N=120) will be compared with the addition of the DynamiCare Health Contingency Management App (TAU+DCM, N=120). DCM is a personal digital therapy tool provided as an app on the patient's smartphone. Its central feature is the delivery of evidence-based contingency management therapy in a convenient, remote, and fully automated fashion that ensures validity of target behaviors and immediacy of reward delivery.

Two target behaviors relevant to retention will be the primary focus of the DCM program: 1) abstinence from opiates and cocaine as verified via remote oral fluid testing, and 2) medication pickup from the methadone program as verified by clinic records. Participants in the TAU+DCM arm will receive financial rewards for achieving these pre-determined behavioral targets over a 48-week intervention period.

Comprehensive assessment of all participants will be conducted at baseline, 3-, 6-, and 12-months.

Aim 1: To determine the relative effectiveness of TAU+DCM compared to TAU alone in improving methadone treatment retention through 12-months post-treatment entry.

Aim 2: To determine the relative effectiveness of TAU+DCM compared to TAU alone in terms of [Aim 2A] reducing opioid use and cocaine use; and [Aim 2B] improving other secondary outcomes including non-targeted substance use and quality of life through 12-months post-treatment entry.

Aim 3: To explore app use patterns, acceptability, and perceived value of the personalized treatment intervention through 12-months post-treatment entry.

Innovation lies in the platform and structure of CM delivery that ensures treatment fidelity with automation of remote behavioral monitoring and reward delivery without involvement of clinical staff. This project represents a novel application of digital therapeutics to enhance the effectiveness of OUD treatment with polysubstance use.

Findings from this project can improve the public health impact of methadone treatment by identifying an effective and scalable approach to address polysubstance use among patients at heightened risk of treatment dropout.

Friends Research Institute

TO SUPPORT BASIC AND CLINICAL NEUROSCIENCE, BIOMEDICAL, BEHAVIORAL AND SOCIAL SCIENCE, EPIDEMIOLOGIC, HEALTH SERVICES AND HEALTH DISPARITY RESEARCH. TO DEVELOP NEW KNOWLEDGE AND APPROACHES RELATED TO THE PREVENTION, DIAGNOSIS, TREATMENT, ETIOLOGY, AND CONSEQUENCES OF DRUG ABUSE AND ADDICTION, INCLUDING HIV/AIDS. TO SUPPORT RESEARCH TRAINING AND RESEARCH SCIENTIST DEVELOPMENT. TO SUPPORT DISSEMINATION OF RESEARCH FINDINGS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) LEGISLATION IS INTENDED TO EXPAND AND IMPROVE THE SBIR PROGRAMS TO EMPHASIZE AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF TECHNOLOGY DEVELOPED THROUGH FEDERAL SBIR RESEARCH AND DEVELOPMENT, INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN THE SBIR PROGRAM. THE LEGISLATION INTENDS THAT THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.

93.279 - Drug Abuse and Addiction Research Programs

National Institute on Drug Abuse (NIDA) [HHS - NIH]

Baltimore, Maryland 212015633 United States

Single Zip Code

HEAL Initiative: Understanding Polysubstance Use and Improving Service Delivery to Address Polysubstance Use (R01 Clinical Trial Optional) (RFA-DA-22-047)

Amendment Since initial award the End Date has been extended from 09/29/25 to 07/31/27 and the total obligations have increased 34% from $2,254,579 to $3,027,776.